American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 741-750 , May 2009

Focused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD

  • Michael J. Koren, MD

      Affiliations

    • Jacksonville Center for Clinical Research, Jacksonville, FL
    • Corresponding Author InformationAddress correspondence to Michael J. Koren, MD, Jacksonville Center for Clinical Research, 4085 University Blvd S, Ste 1, Jacksonville, FL 32216
    • ,
  • Michael H. Davidson, MD

      Affiliations

    • Section of Cardiology, Pritzker School of Medicine, University of Chicago, Chicago, IL
    • ,
  • Daniel J. Wilson, MD

      Affiliations

    • Pfizer Inc, New York, NY
    • ,
  • Rana S. Fayyad, PhD

      Affiliations

    • Pfizer Inc, New York, NY
    • ,
  • Andrea Zuckerman, MD

      Affiliations

    • Pfizer Inc, New York, NY
    • ,
  • David P. Reed, MD

      Affiliations

    • Pfizer Inc, New York, NY
    • ,
  • ALLIANCE Investigators

Received 10 July 2008 ,Accepted 11 November 2008.

References 

  1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047
  2. National Kidney Foundation. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1–S266
  3. US Renal Data System. USRDS 2007 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007;
  4. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–2169
  5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305
  6. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? (National Kidney Foundation Task Force on Cardiovascular Disease). Am J Kidney Dis. 1998;32:853–906
  7. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(suppl 3):S112–S119
  8. Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in chronic kidney disease: Overall burden and rates of treatment and control. Arch Intern Med. 2006;166:1884–1891
  9. Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int. 2006;70:2021–2030
  10. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110:1557–1563
  11. Shepherd J, Kastelein JJP, Bittner V, et al. TNT (Treating to New Targets) Investigators Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: The Treating to New Targets (TNT) Study. J Am Coll Cardiol. 2008;51:1448–1454
  12. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248
  13. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003;14:1605–1613
  14. Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005;112:171–178
  15. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41:565–570
  16. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease (A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study). J Clin Pathol. 2004;57:728–734
  17. Shepherd J, Kastelein JJP, Bittner V, et al. TNT (Treating to New Targets) Investigators Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The Treating to New Targets (TNT) Study. Clin J Am Soc Nephrol. 2007;2:1131–1139
  18. Koren MJ, Hunninghake DB ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: The ALLIANCE Study. J Am Coll Cardiol. 2004;44:1772–1779
  19. Isaacsohn JL, Davidson MH, Hunninghake D, Singer R, McLain R, Black DM. Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)—Rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. Am J Cardiol. 2000;86:250–252
  20. Brosius FC, Hostetter TH, Kelepouris E, et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: A science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: Developed in collaboration with the National Kidney Foundation. Circulation. 2006;114:1083–1087
  21. Levey AS, Greene T, Kusek J, Beck G MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000;11:0828A;(abstr)
  22. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: A meta-analysis. J Am Soc Nephrol. 2006;17:2006–2016
  23. Rahman M, Baimbridge C, Davis BR, et al. ALLHAT Collaborative Research Group Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis. 2008;52:412–424
  24. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998–3007
  25. Moorhead JF. Lipids and progressive kidney disease. Kidney Int Suppl. 1991;31:S35–S40
  26. Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on renal function. Am J Kidney Dis. 2005;45:2–14
  27. Stern RH, Yang BB, Horton M, Moore S, Abel RB, Olson SC. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. J Clin Pharmacol. 1997;37:816–819
  28. Lins RL, Matthys KE, Verpooten GA, et al. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol Dial Transplant. 2003;18:967–976

 Originally published online as doi:10.1053/j.ajkd.2008.11.025 on February 12, 2009.

 For a list of ALLIANCE Investigators, please see reference 18.

PII: S0272-6386(08)01760-5

doi: 10.1053/j.ajkd.2008.11.025

American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 741-750 , May 2009

Article Tools

* Image Usage & Resolution